Tweet
Anyone found a 96 well clean up method that will remove 100 nt/bp and smaller from ~250 bp product? Most give 100 bp as the cutoff, but we've gotten too much small material back with Qiaquick 96. Alternative is Ampure, and it can be tricky to handle in 96 well plate. We'd like to clean up, quantitate, THEN pool and size select to get rid of rest of small material before sequencing. Have tried quantitation, pooling, then clean up and size selection, and dataset yields vary too much. Thanks; Hilary
-
-
We've had success with the 96 Well PureLink Pro kit from Invitrogen
Hope this helps. -
Nothing will outperform AMPure IMHO. You'll probably have to titrate the cut (specifically the binding time and HOW you mix [static vs constant mixing]) in your own hands, but I would start with 1.3-1.4x for that separation range.Comment
-
Proteomics platforms are evolving rapidly, with advances in mass spectrometry and affinity-based approaches expanding what researchers can detect and at what scale. As the field moves toward deeper proteome coverage and clinical applications, scientists face an increasingly complex landscape of tools. This article will explore how researchers are navigating these choices to find the right platform for their work.
The systematic characterization of the human proteome has...07-20-2026, 11:48 AM -
Genomics studies in neuroscience face a special challenge due to the brain’s complexity and scarcity of samples. Mapping changes in cell type and state using conventional next-generation sequencing methods remains challenging. Advances in technologies like single-cell sequencing, spatial transcriptomics, and long-read sequencing have opened the door to deeper studies of the brain and diseases like Alzheimer’s, amyotrophic lateral sclerosis (ALS), and schizophrenia.
...07-09-2026, 11:10 AM -
Cancer survival rates have significantly increased in the last few decades in the United States, reaching a combined 70% 5-year survival rate by 2021. Behind this number, there are years of research to find new therapies, drug targets, and early detection methods. But there is one core challenge that keeps slowing down these advances, and it’s about drug resistance.
There is no single reason why many patients don’t respond to treatment as expected. Cancer is...07-08-2026, 05:17 AM
Comment